India's Rare-Disease Drug Access Gets a Boost through Policy Reforms
India is taking significant steps to improve access to rare-disease treatments through price regulation, subsidies for orphan drugs, and simplified approval pathways. Rare diseases affect a small number of people individually but millions worldwide, posing severe financial and healthcare challenges due to high costs and lack of awareness. Government initiatives aim to reduce financial burdens, support healthcare equity, and boost domestic research in biopharmaceuticals. Collaborative efforts with international pharma companies and strengthening healthcare infrastructure are crucial moving forward.
Key Points
- The government is working on price regulation and subsidies to tackle the high cost of orphan drugs.
- Simplified approval pathways are being introduced for rare-disease treatments and new therapies.
- Global collaborations with international pharma companies and multilateral agencies aim to ensure supply and innovation.
- Key challenges include high treatment costs, complex regulatory processes, lack of awareness, and underdiagnosis.
Exam Facts
- Rare diseases are estimated to affect 300 million people globally, representing about 1 in 17 individuals.
- World Health Organization (WHO) defines rare diseases as conditions affecting a small number of people requiring specialized treatment.
Read it. Retain it. Recall it.
Daily MCQs with explanations, one-line fact cards and topic-wise accuracy. Free on Android, no ads.